💊#FDA Approval Update | #Avlayah: the first therapy targeting neurological symptoms of Hunter syndrome
🧠 Designed to cross the BBB, addressing a major unmet need in this #RareDisease
📉 ~91% reduction in #CSF heparan sulfate in trials
🧪MCE provides tividenofusp alfa for research use
#HunterSyndrome